Moreover, our data highlight the (PI3K)–AKT–mTOR–HIF1α–ACLY-axis as a genotype-specific therapeutic vulnerability in aggressive T cell lymphomas with defective PD-1 function, which should be tested in future clinical interventions. Here, ACLY is linked to T-cell non-Hodgkin lymphoma.